

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-17. (Canceled)

18. (Currently Amended) A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants and a second component selected from the group consisting of antibodies, or and antigen-binding fragments thereof, that specifically bind to a protein comprising the amino acid sequence of SEQ ID NO: 114 amino acid residues 120-139, 151-169 or 165-184 of SEQ ID NO: 114.

19. (Previously Presented) The composition of claim 18, wherein the antibodies or antigen-binding fragments thereof are polyclonal antibodies or antigen-binding fragments thereof.

20. (Previously Presented) The composition of claim 18, wherein the antibodies or antigen-binding fragments thereof are monoclonal antibodies or antigen binding fragments thereof.

21. (Currently Amended) The An isolated monoclonal antibody composition of claim 20, wherein the monoclonal antibodies or antigen-binding fragments thereof that specifically binds to a sequence selected from the group consisting of amino acid residues 120-139, 151-169 or 165-184 of SEQ ID NO: 114.

22. (Previously Presented) The composition of claim 18, wherein the composition is effective for inhibiting tumor growth.